Captopril, classified under HS code 30049071, is exported to several key markets, including Tanzania, the United States, Belgium, the Dominican Republic, South Africa, the Democratic Republic of the Congo (DRC), Venezuela, and Rwanda. Understanding the Most Favored Nation (MFN) tariff rates, preferential rates under Free Trade Agreements (FTAs) with India, and any exemptions for essential medicines in these countries is crucial for optimizing trade operations.
- Tanzania: As a member of the East African Community (EAC), Tanzania applies the EAC Common External Tariff (CET). Pharmaceutical products, including those under HS code 3004, are typically subject to a 0% import duty, recognizing their essential nature. India and the EAC have engaged in trade discussions, but as of now, no specific FTA provides additional tariff preferences for pharmaceutical imports.
- United States: The U.S. Harmonized Tariff Schedule (HTS) classifies Captopril under subheading 3004.90. Pharmaceutical products under this classification are generally duty-free under the MFN rate. The U.S. does not have an FTA with India that affects tariffs on pharmaceutical imports; however, the duty-free status facilitates trade.
- Belgium: As a European Union (EU) member, Belgium adheres to the EU's Common External Tariff. Medicaments under HS code 3004 are typically subject to a 0% MFN tariff rate. The EU-India trade relations are governed by the Generalized System of Preferences (GSP), which may offer reduced tariffs for certain products, though pharmaceutical products often already benefit from zero tariffs.
